ArticleMycopathologia2026
A New Medium that Promotes In Vitro Mass Sporulation of Microsporum canis.
Article in Mycopathologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Microsporum canis is one of the most common zoophilic pathogenic fungi, and infections are typically managed using empirical antifungal therapy. The increasing incidence of M. canis infections has led to a growing demand for antifungal susceptibility assays in clinical settings, particularly in pediatric department, to guide drug selection and to monitor therapeutic responses in highly inflammatory cases. However, susceptibility testing methods rely heavily on sporulation capacity of M. canis, and more than half of the clinical isolates fail to produce sufficient microconidia in commonly-used media for reliable testing.In this study, we evaluated a novel a rice bran medium (RBM) for its ability to enhance microconidia production in clinical isolates of M. canis. RBM demonstrated a significantly greater sporulation-inducing effect than conventional media, including potato dextrose agar (PDA), Sabouraud dextrose agar (SDA), and oatmeal agar (OA), which are commonly used in clinical laboratories. Sporulation efficiency varied with RBM concentrations, with 4% RBM showing the highest efficacy. Under this concentration, abundant microconidia were consistently produced by testing clinical strains after 7-10 days of incubation at 30 ℃ across. These findings suggest that RBM represents a practical and effective alternative medium for promoting sporulation and facilitating antifungal susceptibility in clinical settings.
Indexed as
Identifiers
41813878What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.